Evidence map›Paper›PMID 33779866›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

Cerebrovascular and cardiovascular disease burden in patients with hereditary hemorrhagic telangiectasia.

Mudassir Farooqui, Sajid Suriya, Fares Qeadan, Catherine Vigil, Ashley Wegele, Asad Ikram, Syed A Quadri, Myranda Robinson, Josanna Rodriguez-Lopez, Santiago Ortega-Gutierrez and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mudassir FarooquiDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Sajid SuriyaDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Fares QeadanDepartment of Family and Preventive Medicine, University of Utah, Salt Lake City, UT, USA.
Catherine VigilHarvard University, Cambridge, MA, USA.
Ashley WegeleDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Asad IkramDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Syed A QuadriDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Myranda RobinsonDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Josanna Rodriguez-LopezDivision of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Santiago Ortega-GutierrezDepartment of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Atif ZafarDepartment of Neurology, University of New Mexico Health Sciences Center, University of New Mexico, MSC-10-5620, 1 University of New Mexico, Albuquerque, NM, 87131, USA. Atif.Zafar@unityhealth.to.ORCID http://orcid.org/0000-0002-2738-5225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHereditary hemorrhagic telangiectasia (HHT) is a rare genetic disease with prevalence of approximately 1 in 5000-10,000. We evaluated the prevalence and association of cerebrovascular and cardiovascular comorbidities in HHT patients using national database.

methodsRetrospective observational study was performed using National Inpatient Sampling (NIS) database for the year 2014. HHT patients and comorbidities were identified using ICD-9 codes. Univariate and multivariate analyses were performed using SAS.

resultsPrevalence of HHT was 0.0119% with predominance in White population. Mean age of HHT patients was 59 years. Increased proportion of HHT patients had hypertension (46.8% vs 42%), anemia (28.9% vs 15.1%), chronic pulmonary disease (24.8% vs 16.4%), congestive heart failure (15.7% vs 7.5%), liver disease (7.9% vs 2.8%), migraine (4.5% vs 1.5%), and cerebrovascular malformations (0.8% vs 0.03%), whereas chronic kidney disease (12.7% vs 12.2%), headaches (1.3% vs 1.1%), seizures (0.7% vs 0.9%), transient ischemic attacks (1.06% vs 1.03%), ischemic (1.2% vs 1.0%), and hemorrhagic (0.5% vs 0.3%) strokes were similar to those without HHT. Multivariable model shows increase in cerebrovascular malformations (OR 11.04, CI 2.49-22.26, p < 0.0001), migraine (OR 3.23, CI 2.30-4.52, p < 0.0001), chronic blood loss anemia (OR 6.83, CI 5.36-8.71, p < 0.0001), congestive heart failure (OR 1.55, CI 1.26-1.91, p < 0.0001), chronic pulmonary disease (OR 1.30, CI 1.09-1.56, p = 0.0038), and hepatic disease (OR 2.63, CI 2.01-3.45, p < 0.0001) in HHT patients as compared to non-HHT patients.

conclusionThere is a need for a large prospective registry of HHT patients that can corroborate these associations and burden of cerebrovascular and cardiovascular diseases.

Indexed as

Cardiovascular DiseasesCardiovascular SystemTelangiectasia, Hereditary HemorrhagicCost of IllnessHumansMiddle AgedPrevalenceGeneticHereditary hemorrhagic telangiectasiaHHTNational inpatient samplingOsler-Weber-Rendu syndrome

Identifiers

PMID33779866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.